孙青,李晓燕,刘娟,张红明,张国明,韩淑芳,陈英剑

• 1:济南军区总医院心内科
• 2:济南军区总医院检验科

摘要(Abstract)：

目的探讨血浆过氧化物酶体增殖物激活受体γ(PPARγ)对急性冠状动脉综合征(ACS)合并2型糖尿病(T2DM)患者冠状动脉病变程度及斑块稳定性的影响。方法选取确诊的ACS患者102例,其中合并2型糖尿病52例(51.0%,ACS+T2DM组),单纯ACS患者50例(49.0%,ACS组)。选取正常对照30例(对照组)。行冠状动脉造影术(CAG)并应用Gensini积分系统进行冠状动脉狭窄程度评估;所有患者抽取静脉血应用ELISA检测血浆PPARγ、基质金属蛋白酶-9(MMP-9)水平,并进行相关性分析。结果 ACS+T2DM组Gensini积分显著大于ACS组(P<0.05)。与对照组相比,ACS+T2DM组、ACS组血浆PPARγ水平下降,MMP-9浓度显著升高,ACS+T2DM组PPARγ下降、MMP-9升高更明显,组间比较差异均有统计学意义(P均<0.05)。ACS+T2DM组PPARγ浓度与Gensini积分(r=-0.416,P<0.05)、MMP-9浓度(r=-0.503,P<0.05)均呈负相关趋势。结论合并2型糖尿病能够加剧ACS患者冠状动脉病变及斑块不稳定程度,PPARγ可能在其中起保护作用。

关键词(KeyWords)： 急性冠状动脉综合征;2型糖尿病;过氧化物酶体增殖物激活受体γ;基质金属蛋白酶-9;Gensini积分

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 孙青,李晓燕,刘娟,张红明,张国明,韩淑芳,陈英剑

参考文献(References)：

• [1]Stamler J,Vaccaro O,Neaton JD,et al.Diabetes,other risk factors,and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.Diabetes Care,1993,16:434-444.
• [2]Hu DY,Pan CY,Yu JM,et al.The relationship between coronary artery disease and abnormal glucose regulation in China:the China Heart Survey.Eur Heart J,2006,27:2573-2579.
• [3]Zeng B,Prasan A,Fung KC,et al.Elevated circulating levels of matrix metalloproteinase-9 and-2 in patients with symptomatic coronary arterydisease.Intern Med J,2005,35:331-335.
• [4]Stamler J,Vaccaro O,Neaton JD,et al.Diabetes,other risk factors,and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.Diabetes Care,1993,16:434-444.
• [5]郑凌飞,韩雅玲,荆全民,等.2型糖尿病与冠状动脉病变程度的相关性分析.中国介入心脏病学杂志,2012,20:67-71.
• [6]Gómez-Hernández A,Martín-Ventura JL,Sánchez-Galán E,et al.Overexpression of COX-2,Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cellsand plaque of patients with carotid atherosclerosis:regulation by nuclear factorkappaB.Atherosclerosis,2006,187:139-149.
• [7]Brown DL,Hibbs MS,Keamey M,et al.Identification of 92-KD gelatinase in human coronary atherosclerotis lesion:association of active enzyme synthesis with unstable angina.Circulation,1995,91:2125-2131.
• [8]Abbas A,Blandon J,Rude J,et al.PPAR-γagonist in treatment of diabetes:cardiovascular safety considerations.Cardiovasc Hematol Agents Med Chem,2012,10:124-134.
• [9]Marx N,Kehrle B,Kohlhammer K,et al.PPAR activators as antiinfl ammatory mediators in human T lymphocytes:implications for atherosclerosis and transplantation-associated arteriosclerosis.Circ Res,2002,90:703-710.
• [10]Malerd L,Sporstl M,Juvet LK,et al.Hepatic scavenger receptor class B,type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha.Biochem Biophys Res Commun,2003,305:557-565.
• [11]Sugawara A,Takeuchi K,Uruno A,et al.Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells.Endocrinology,2001,142:3125-3134.